Melanocyte stimulating hormone release inhibiting factor is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body.
CAT No: R1833
CAS No: 2002-44-0
Synonyms/Alias: 2002-44-0;MELANOSTATIN;MIF-1;L-Prolyl-L-leucylglycinamide;Oxytocin C-terminal tripeptide;Pro-Leu-Gly-NH2;MIF-I;7-9-Oxytocin;Melanostatin I (ox);(S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide;Prolylleucylglycine amide;MSH-release inhibiting factor I;C13H24N4O3;(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide;L-Prolyl-L-leucylglycylamide;Glycinamide, L-prolyl-L-leucyl-;L-Proline-L-leucine-glycine-amide;CHEMBL317488;3KY24B4Q62;(2S)-N-(carbamoylmethyl)-4-methyl-2-{[(2S)-pyrrolidin-2-yl]formamido}pentanamide;Pro-Leu-Gly amide;UNII-3KY24B4Q62;Prolyl-L-leucyl-glycinamide, L-;EINECS 217-902-7;L-pro-L-leu-gly-NH2;MELANOSTATIN MIF-I;SCHEMBL362530;MELANOSTATIN MIF-I [MI];DTXSID20173841;CHEBI:168693;NOOJLZTTWSNHOX-UWVGGRQHSA-N;MIF-I, (-)-;BBL033793;BDBM50060601;HB1874;MFCD00037866;MFCD08282654;STL372235;2-Pyrrolidinecarboxamide, N-(1-((carbamoylmethyl)carbamoyl)-3-methylbutyl)-;AKOS015955826;MSH RELEASE-INHIBITING FACTOR I;(2S)-N-(carbamoylmethyl)-4-methyl-2-[(2S)-pyrrolidin-2-ylformamido]pentanamide;(S)-N-((S)-1-(2-amino-2-oxoethylamino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide;DA-66890;FM109235;NS-04720;PD070730;HY-107663;CS-0029128;NS00026500;EN300-302728;6-((E)-3-Oxo-3-phenyl-propenyl)-1H-pyrimidine-2,4-dione;(E)-6-(3-oxo-3-phenylprop-1-enyl)pyrimidine-2,4(1H,3H)-dione;(S)-Pyrrolidine-2-carboxylic acid [(S)-1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide;Pyrrolidine-2-carboxylic acid [1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide;
Chemical Name: (2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C13H24N4O3 |
M.W/Mr. | 284.35 |
Sequence | One Letter Code:PLG Three Letter Code:H-Pro-Leu-Gly-NH2 |
Long-term Storage Conditions | ≥59.1mg/mL in DMSO |
Shipping Condition | Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request. |
InChI | InChI=1S/C13H24N4O3/c1-8(2)6-10(12(19)16-7-11(14)18)17-13(20)9-4-3-5-15-9/h8-10,15H,3-7H2,1-2H3,(H2,14,18)(H,16,19)(H,17,20)/t9-,10-/m0/s1 |
InChI Key | NOOJLZTTWSNHOX-UWVGGRQHSA-N |
Canonical SMILES | CC(C)CC(C(=O)NCC(=O)N)NC(=O)C1CCCN1 |
Isomeric SMILES | CC(C)C[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1 |
3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
4. The spatiotemporal control of signalling and trafficking of the GLP-1R
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com